Among these, germline or somatic alterations in BRCA2 are the most common, accounting for 6–12% of cases across studies.2, 3, 4 These data underpin the evaluation of poly(ADP-ribose) polymerase (PARP) inhibitors in metastatic prostate cancer.5, 6. This evidence concerns the gene PARP1 and metastatic prostate carcinoma.